Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $10.5 million.

  • Lineage Cell Therapeutics' Net Cash Flow rose 5.68% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 422.35%. This contributed to the annual value of $10.5 million for FY2024, which is 56.98% down from last year.
  • Lineage Cell Therapeutics' Net Cash Flow amounted to $10.5 million in FY2024, which was down 56.98% from $24.3 million recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Net Cash Flow high stood at $24.3 million for FY2023, and its period low was -$43.5 million during FY2022.
  • Over the past 3 years, Lineage Cell Therapeutics' median Net Cash Flow value was $10.5 million (recorded in 2024), while the average stood at -$2.9 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Net Cash Flow surged by 261.07% in 2020 and then tumbled by 288.06% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Net Cash Flow (Yearly) stood at $23.1 million in 2020, then fell by 0.16% to $23.1 million in 2021, then crashed by 288.06% to -$43.5 million in 2022, then soared by 155.92% to $24.3 million in 2023, then plummeted by 56.98% to $10.5 million in 2024.